PBAC's latest decision on Olmesartan medoxomil with hydrochlorothiazide: Recommended with restriction (2007). Considered for Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or olmesartan monotherapy.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2007
Submissions
1
2007 → 2007
Eligible population
patients with hypertension unresponsive to monotherapy with either olmesartan or hydrochlorothiazide
Therapy area
Cardiovascular
Line of therapy
Not applicable
Evidence base
RCT
Key trials
Sellin et al (2005), Chrysant et al (2004)
Comparator
olmesartan medoxomil and hydrochlorothiazide taken concomitantly